[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649932":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":10,"responsibleParty":30,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":10,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":10},{"fullName":5,"class":6},"IRCCS San Raffaele","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study cohort",null,"Collection of peripheral blood (up to 50 ml) for the analysis of the biological activity of IRAK4 Chimeric Degradation Activation Compound (CDAC) in purified CLL B cells, assessed by changes in proliferation, apoptosis, and signaling pathway activation following in vitro treatment.",[13],"Procedure: Peripheral blood sample collection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Peripheral blood sample collection","Up to 50 ml of blood will be collected for the research project at the time of standard blood tests.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Paolo Ghia, MD, PhD","CONTACT","+390226434797","ghia.paolo@hsr.it",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Lydia Scarfo, MD","+390226436119","scarfo.lydia@hsr.it",{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Paolo Ghia","Prof","100649932","targeting-irak4-in-chronic-lymphocytic-leukemia-100649932",false,"NCT07741695","Targeting IRAK4 in Chronic Lymphocytic Leukemia","PS-CLL016","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of CLL\n* Participant is willing and able to give informed consent for participation in the study.\n\nExclusion Criteria:\n\n\\- Participant is unable or unwilling to provide informed consent for participation in the study","ALL","18 Years",{"count":44,"type":45},50,"ESTIMATED","OBSERVATIONAL","Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC).",[49],"Chronic Lymphocytic Leukemia (CLL)",[51,52],"chronic lymphocytic leukemia","IRAK4","NOT_YET_RECRUITING","2026-08-03",{"date":56,"type":57},"2026-08-04","ACTUAL",{"date":59,"type":45},"2026-09",{"date":61,"type":45},"2027-09",{"name":5,"class":6}]